681 related articles for article (PubMed ID: 17363594)
1. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
Jain RK; Tong RT; Munn LL
Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin.
Dafni H; Israely T; Bhujwalla ZM; Benjamin LE; Neeman M
Cancer Res; 2002 Nov; 62(22):6731-9. PubMed ID: 12438274
[TBL] [Abstract][Full Text] [Related]
3. The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems.
Wu M; Frieboes HB; McDougall SR; Chaplain MA; Cristini V; Lowengrub J
J Theor Biol; 2013 Mar; 320():131-51. PubMed ID: 23220211
[TBL] [Abstract][Full Text] [Related]
4. The effect of interstitial pressure on therapeutic agent transport: coupling with the tumor blood and lymphatic vascular systems.
Wu M; Frieboes HB; Chaplain MA; McDougall SR; Cristini V; Lowengrub JS
J Theor Biol; 2014 Aug; 355():194-207. PubMed ID: 24751927
[TBL] [Abstract][Full Text] [Related]
5. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
6. Numerical simulation of the tumor interstitial fluid transport: Consideration of drug delivery mechanism.
Moghadam MC; Deyranlou A; Sharifi A; Niazmand H
Microvasc Res; 2015 Sep; 101():62-71. PubMed ID: 26122936
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
8. Role of the VEGF/VEGFR axis in cancer biology and therapy.
Rapisarda A; Melillo G
Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
[TBL] [Abstract][Full Text] [Related]
9. Effect of pazopanib on tumor microenvironment and liposome delivery.
Tailor TD; Hanna G; Yarmolenko PS; Dreher MR; Betof AS; Nixon AB; Spasojevic I; Dewhirst MW
Mol Cancer Ther; 2010 Jun; 9(6):1798-808. PubMed ID: 20515941
[TBL] [Abstract][Full Text] [Related]
10. Tumor interstitial fluid pressure-a link between tumor hypoxia, microvascular density, and lymph node metastasis.
Rofstad EK; Galappathi K; Mathiesen BS
Neoplasia; 2014 Jul; 16(7):586-94. PubMed ID: 25117980
[TBL] [Abstract][Full Text] [Related]
11. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
12. Effect of wall compliance and permeability on blood-flow rate in counter-current microvessels formed from anastomosis during tumor-induced angiogenesis.
Guo P; Fu BM
J Biomech Eng; 2012 Apr; 134(4):041003. PubMed ID: 22667678
[TBL] [Abstract][Full Text] [Related]
13. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors.
Skliarenko JV; Lunt SJ; Gordon ML; Vitkin A; Milosevic M; Hill RP
Cancer Res; 2006 Feb; 66(4):2074-80. PubMed ID: 16489007
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
15. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma.
Kłosowska-Wardega A; Hasumi Y; Burmakin M; Ahgren A; Stuhr L; Moen I; Reed RK; Rubin K; Hellberg C; Heldin CH
PLoS One; 2009 Dec; 4(12):e8149. PubMed ID: 19997591
[TBL] [Abstract][Full Text] [Related]
16. Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies.
Akerman S; Fisher M; Daniel RA; Lefley D; Reyes-Aldasoro CC; Lunt SJ; Harris S; Bjorndahl M; Williams LJ; Evans H; Barber PR; Prise VE; Vojnovic B; Kanthou C; Tozer GM
Int J Cancer; 2013 Dec; 133(11):2563-76. PubMed ID: 23712501
[TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy for cancer: current and emerging concepts.
Jain RK
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
[TBL] [Abstract][Full Text] [Related]
19. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Mancuso MR; Davis R; Norberg SM; O'Brien S; Sennino B; Nakahara T; Yao VJ; Inai T; Brooks P; Freimark B; Shalinsky DR; Hu-Lowe DD; McDonald DM
J Clin Invest; 2006 Oct; 116(10):2610-21. PubMed ID: 17016557
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
